Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
Piero Barbanti(Vita-Salute San Raffaele University), Fabrizio Vernieri(Università Campus Bio-Medico), Sabina Cevoli(Istituto delle Scienze Neurologiche di Bologna), Francesco Bono(Azienda Ospedaliero Universitario Mater Domini), Licia Grazzi(Fondazione IRCCS Istituto Neurologico Carlo Besta), Claudia Altamura(Università Campus Bio-Medico), Antonio Salerno(Azienda Ospedaliera San Giovanni Addolorata), B. Mercuri(Azienda Ospedaliera San Giovanni Addolorata), Fabio Frediani(Ospedale San Carlo), Gabriella Egeo(IRCCS Ospedale San Raffaele), Luisa Fofi(Campus Bio Medico University Hospital), Bruno Colombo(Vita-Salute San Raffaele University), Massimo Filippi(Vita-Salute San Raffaele University), Antonio Carnevale(Ospedale San Filippo Neri), Cinzia Aurilia(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 129
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k